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The thalassaemias are a group of inherited blood disorders 
characterised by decreased or absent globin chain synthesis. The 
clinical syndrome of thalassaemia was first described in 1925 by 
Thomas Cooley, a paediatrician from Detroit. He documented a 
constellation of findings, including splenomegaly, severe anaemia 
and bony deformities in children of Italian and Greek descent, which 
became known as Cooley’s anaemia. The syndrome was subsequently 
termed thalassaemia, derived from the Greek words thalassa and 
haima, which translate as sea and blood, respectively, as a high 
prevalence was noted in areas adjacent to the Mediterranean Sea. 
Thalassaemia is the most common monogenic disorder worldwide. 
As with other inherited haemolytic conditions, the geographical 
distribution of the condition has a high degree of overlap with areas 
endemic to malaria, this being a consequence of partial protection 
of heterozygotes (thalassaemia carriers) against malaria. It is this 
survival advantage against malaria and consequent natural selection 
of the heterozygous form that is responsible for elevating and 
maintaining such high gene frequencies.
The proposed mechanisms of protection may be categorised as 
immune related or cellular, and include better immune clearance, 
reduced survival of the malarial parasite within red blood cells and 
diminished parasite capacity for invasion of red blood cells. The 
thalassaemias are most commonly encountered among people of 
Italian, Greek, Middle Eastern, South Asian and African descent. 
Thalassaemia, as well as other inherited haemolytic conditions, 
is increasingly encountered in countries not endemic to malaria 
because of migration.[1]
Classification of thalassaemia is based on the globin chain that is 
deficient. For instance, in α-thalassaemia there is underproduction 
of α-globin chains, and in β-thalassemia there is underproduction 
of β-globin chains. Likewise, in γ- and δ-thalassaemia, there is 
underproduction of γ- and δ-globin chains, respectively. The clinical 
phenotype depends on the number of globin genes affected and 
varies from the asymptomatic state to severe haemolytic anaemia. 
Furthermore, co-inheritance of Hb variants is not uncommon, 
e.g. sickle cell disease or HbE may be co-inherited with α- or 
β-thalassaemia, which results in a diverse set of clinical phenotypes.
The advent of next-generation sequencing (NGS) represents a 
significant advance in the diagnosis of inherited red cell disorders. Apart 
from elucidating genetic defects, NGS allows for simultaneous detection 
of co-existing abnormalities, providing greater insight into genotype-
phenotype associations and aiding the course of genetic counselling. 
Human Hb is a tetrameric molecule that is comprised of two α- and 
two non-α-globin chains. Postnatally, three Hb subtypes exist, 
viz. HbA (α2,β2), HbF (α2,γ2) and HbA2 (α2,δ2), each comprising 
>95%, <2% and 2.4 - 3.7% of the total Hb, respectively. These 
proportions are reached at the end of the first year of life. Since HbA 
constitutes the major fraction of total Hb, the α- and β-thalassaemias 
represent the bulk of clinically significant thalassaemias, and are 
therefore the focus of this 2-part CME series. In this issue (part 1),[2] 
the discourse centres around epidemiology, pathophysiology, clinical 
exposition and diagnosis. Management issues are discussed in the 
forthcoming issue (part 2).
The authors are indeed grateful for the opportunity to discuss the 
topic of thalassaemia, a subject that is often 
not clearly understood owing to variable 
genotype-phenotype associations.
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